Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
Diabetes Metab Syndr. 2022 Mar;16(3):102427. doi: 10.1016/j.dsx.2022.102427. Epub 2022 Feb 12.
The importance of glucagon-like peptide-1 (GLP-1) agonists is increasing because of its blood sugar controlling and weight loss properties. The data regarding safety of GLP-1 agonists are limited. This study aims to review case reports and case series on adverse drug reactions (ADRs) of GLP-1 agonist.
A comprehensive search was performed in PubMed/Medline, Scopus and Embase to identify literatures. Bibliographic search and open search in Google, Google Scholar, SpringerLink and ResearchGate was performed to identify additional studies. Case reports and case series published the ADRs by the use of GLP-1 agonists in type 2 diabetes patients were included in the study. Reviews, experimental studies, observational studies, grey literature and non English studies were excluded.
The study identified 120 cases of GLP-1 agonists associated ADRs (liraglutide - 46, exenatide - 46, dulaglutide - 20, semaglutide - 4, albiglutide - 2, lixisenatide - 2). The major ADRs reported was gastrointestinal disorders (n = 40) followed by renal (n = 23), dermatologic (n = 14), hepatic (n = 10), immunologic (n = 13), endocrine/metabolic (n = 7), hematologic (n = 3), angioedema (n = 3), neurologic (n = 2), cardiovascular (n = 2) and 1 from each of psychiatric, reproductive, generalized edema problems.
Gastrointestinal problems, particularly pancreatitis was the more frequently reported adverse drug reaction associated with GLP-1 agonist. The most adverse drug reactions were observed with liraglutide and exenatide.
胰高血糖素样肽-1（GLP-1）激动剂因其具有控制血糖和减肥的特性而变得越来越重要。关于 GLP-1 激动剂安全性的数据有限。本研究旨在综述 GLP-1 激动剂不良药物反应（ADR）的病例报告和病例系列。
在 PubMed/Medline、Scopus 和 Embase 中进行全面检索，以确定文献。在 Google、Google Scholar、SpringerLink 和 ResearchGate 中进行文献检索和开放式搜索，以确定其他研究。纳入研究的病例报告和病例系列报告了 2 型糖尿病患者使用 GLP-1 激动剂引起的 ADR。综述、实验研究、观察性研究、灰色文献和非英语文献被排除在外。
研究共确定了 120 例与 GLP-1 激动剂相关的 ADR（利拉鲁肽 46 例，艾塞那肽 46 例，度拉糖肽 20 例，司美格鲁肽 4 例，阿必鲁肽 2 例，利西拉肽 2 例）。报告的主要 ADR 是胃肠道疾病（n=40），其次是肾脏（n=23）、皮肤（n=14）、肝脏（n=10）、免疫（n=13）、内分泌/代谢（n=7）、血液（n=3）、血管性水肿（n=3）、神经（n=2）、心血管（n=2）和 1 例来自精神科、生殖科、全身性水肿问题。
胃肠道问题，特别是胰腺炎，是与 GLP-1 激动剂相关的更常见的不良药物反应。最常见的不良药物反应发生在利拉鲁肽和艾塞那肽。
